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ABSTRACT
Introduction: Rheumatoid arthritis (RA) is a
chronic autoimmune inflammatory disease, for
which the introduction of injectable treatments
has had a major impact on quality of life
directly related to the disease. The purpose of
this descriptive study was to evaluate the
usability of a new autoinjector, intended for
methotrexate self-administration, based on the
device’s design and instructions for use (IFU).
Methods: This multicenter trial included three
user groups: a group of patients with
established RA subdivided into two groups
according to their hand disability, and a group
of caregivers or nurses. Each subject performed
three simulated injections with a water-filled
device on a foam pad. The first injection was
made just after reading the IFU without further
instructions (first phase). The second phase
consisted of two injections made after expla-
nations provided upon request of the subject
in an optimum environment and in a
‘‘worst-case’’ home environment. The usability
of the autoinjector was assessed by a ques-
tionnaire (success: C75% of positive responses)
and by a score card reflecting injection per-
formances (success: execution of C75% of
handling steps).
Results: Forty-two subjects were enrolled in
the study. During the first phase, the great
majority of subjects succeeded in the usability
questionnaire (90.5%) and in the injection
performance (95.2%) with no major differ-
ences between the user groups. In the Second
phase, all subjects from all three user groups
succeeded in the usability questionnaire and
had a positive rate of device handling,
regardless of the environment and of the user
group. No safety concerns were raised during
the study.
Conclusions: This study found a very high level
of usability and subject acceptance of the
autoinjector, intended for methotrexate
self-administration, regardless of the hand dis-
ability and environmental conditions.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoim-
mune inflammatory disease for which the
introduction of injectable treatments has had a
major impact on quality of life directly related
to the disease. Lack of patient adherence is
considered one of the major issues in contem-
porary medicine. It is thought that improving
patients’ adherence to long-term therapies is
more efficient than any biomedical progress [1].
Several studies have demonstrated that self-in-
jection versus injection by healthcare workers
can increase patients’ treatment adherence, and
reduce costs for society by decreasing the fre-
quency of healthcare professionals’ visits.
Moreover, it also benefits patients in terms of
costs, time, ease of use, improved self-esteem,
and greater quality of life [2, 3].
Patients with RA suffer from reduced manual
dexterity, meaning that administering self-in-
jections correctly can be physically problematic.
Different injection technologies, such as pre-
filled syringes or autoinjectors, have been
introduced. Autoinjectors automatically insert
the needle and deliver a controlled and fixed
dose of the required drug. These devices have
been shown to provide numerous benefits,
including a reduced risk of injection site reac-
tions, reduced discomfort and greater ease of
use compared with classic syringes [4, 5].
This study aimed to evaluate the usability of
a newly developed autoinjector intended for
methotrexate (MTX) administration, NORDi-
MET (methotrexate), Nordic Group BV,
Hoofddorp, The Netherlands, recently approved
by the European Medicines Agency for the
management of adult patients with active RA
[6]. This labeling occurred after the end of the
study. The trial was conducted in 42 subjects,
divided into three user groups: a group of
patients with established RA subdivided into
two groups according to their hand disability,
and a group of caregivers or nurses with expe-
rience in treating patients directly. The study
population is a reflection of the foreseen user
population of the device.
METHODS
Investigators and Patients
This was a multicenter usability study, per-
formed in France in compliance with Good
Clinical Practice according to European direc-
tives and French laws (EudraCT reference
number: 2014-A0141245). The investigators
were three rheumatologists with mixed private/
hospital activity. All study assessments were
performed during a single consultation.
The trial was carried out with 42 subjects
allocated to three user groups. The first two
groups were composed of RA patients split by
their hand disability measured by Cochin scale
[7, 8] (Table 1). Patients with high hand dis-
ability (Cochin score C20) and low hand dis-
ability (Cochin score \20) were enrolled
respectively in groups 1 and 2. The third group
was composed of professional nurses or care-
givers already involved in RA patients’ treat-
ment. For RA patients, any previous treatment
by any auto-injector device was an exclusion
criterion.
Study Product and Simulated Injections
The study product was an autoinjector from
SHL Group aimed to MTX subcutaneous (SC)
self-administration. It is a single-use, disposable,
fixed-dose needle-based injection system with
automatic functionality (NIS-AUTO) device
(Fig. 1).
After the removal of the cap, the button-free
device is activated simply by pressing the needle
shield directly against the injection site and
holding it during the MTX distribution (maxi-
mum duration of 10 s). The beginning and the
end of the injections are signaled to the subject
by sounds, called ‘‘clicks’’ and by slight
vibrations.
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For this study, the autoinjector has been
assembled with a pre-filled glass syringe con-
taining 0.6 ml water for injection. No active
MTX was used in the study and only
simulated-use of the autoinjector was per-
formed on foam pads mimicking skin behavior
(Fig. 2).
Study Design
All the subjects included in the study were C18
years old and were able to understand the study
procedures, which was materialized by signing
the informed consent. Additional inclusion
criteria for the first two groups were: RA,
according to 2010 ACR/EULAR classification [9];
Cochin score C20 for the first group and Cochin
score \20 for the second group; absence of
previous treatment by any autoinjector device.
The study consisted of two phases. During
the first phase, the instructor (a trained person
from the investigator’s staff or the investigator
himself/herself) gave the autoinjector and its
instructions for use (IFU) to the subject without
further explanations. Immediately after reading
the IFU, the subject performed the first simu-
lated injection, his/her performances were
evaluated by an independent observer using a
detailed questionnaire, called ‘‘score card’’
(Table 2).
At the end of the simulated injection, the
instructor interviewed the subject and
Table 1 The Cochin scale
In the kitchen
1. Can you hold a bowl?
2. Can you grasp a full bottle and raise it?
3. Can you hold a plate full of food?
4. Can you pour liquid from a bottle into a glass?
5. Can you unscrew the lid from a jar that has been
opened before?
6. Can you cut meet with a knife?
7. Can you prick things well with a fork?
8. Can you peel fruit?
Dressing
9. Can you button your shirt?
10. Can you open and close a zipper?
Hygiene
11. Can you squeeze a tube of toothpaste?
12. Can you hold a toothbrush effectively?
At the ofﬁce
13. Can you write a short sentence with an ordinary
pen?§
14. Can you write a letter with an ordinary pen?§
Other
15. Can you turn a round door knob?
16. Can you cut a piece of paper with scissors?§
17. Can you pick up coins from a table top?§
18. Can you turn a key in a lock?
Answers to the questions: 0 = Yes, without difﬁculty;
1 = Yes, with a little difﬁculty; 2 = Yes, with some difﬁ-
culty; 3 = Yes, with much difﬁculty; 4 = Nearly impossi-
ble to do; 5 = Impossible to do
 Question in factor 2
 Question in factor 1
§ Question in factor 3 after factor analysis
Fig. 1 Description of the autoinjector
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completed the usability questionnaire: part 1
(understanding the IFU and general impression)
and part 2 (usability questionnaire) (Table 3).
At the beginning of the second phase, the
instructor could provide explanations concern-
ing the IFU upon request of the subject. After-
wards, the subject performed two simulated
injections: in an optimal environment (full
light, no noise) and in a ‘‘worst-case’’ home
environment (dimmed light, TV or radio on,
phone ringing). During both simulations, the
independent observer assessed the performance
in compliance with the IFU using the same
‘‘score card’’ as during the first phase. At the end
Fig. 2 Description of the foam pad
Table 2 The score card
Before use Did the subject check through the viewing window if he/she sees a ﬂuid?
Did the subject check if the tamper-evident seal is intact?
During the simulated
injection
Did the subject hold the autoinjector in one hand?
Did the subject pull off the green cap?
Did the subject make a ‘‘skin’’ fold on the pad?
Did he/she make the ‘‘skin’’ fold with the foreﬁnger and thumb?
Did the yellow needle shield point towards the injection site?
Did the subject place the autoinjector on the pad in a (approximately) 90 angle?
Did the subject place the autoinjector on the pad so the entire rim of the yellow needle shield
touched the pad?
Did the subject apply downward pressure on the autoinjector (needle shield fully pushed in) so
that a click was heard?
Did the subject hold the autoinjector with the needle shield fully pushed in until a second click
was heard before removing the autoinjector?
Did the subject wait 2–3 s after the second click before removing the autoinjector?
Did the subject hold the ‘‘skin’’ fold from before the injection until after he/she removed the
autoinjector from the pad?
After use Did the subject look through the viewing window of the autoinjector after the injection?
Did the subject put the green cap back on the autoinjector after the injection?
All the questions were answered by: ‘‘Yes, immediately’’, ‘‘Yes, but after some hesitations or problems’’, or ‘‘No, not at all’’.
The ﬁrst two answers were considered as ‘‘correct handling’’
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Table 3 The usability questionnaire
Part Question Measure
Part 1: Understanding the IFU
(after phase 1)
Did you check the viewing window? Yes/neutral/no
If yes, did you see a ﬂuid in the viewing window?
Did you check the tamper-evident seal of the autoinjector?
If yes, was the tamper-evident seal intact?
Could you see on the autoinjector that the injection was made?
Did you see green plastic after using the autoinjector?
How useful where the pictures in the IFU? Adjusted 5-point
Likert scale*How clear was it how to move the autoinjector towards the site of
injection?
How would you score the setup on the IFU in terms of ability to
follow the handlings steps?
Part 2: Usability (after phase 1
and 2)—subject device
acceptance and system ease of
use




How easy or difﬁcult was it to hold the autoinjector?
How easy or difﬁcult was it to take the cap off?
How would you score the force needed to press on the
autoinjector in order to inject?
How would you score the simplicity of the injection process?
How would you rate the audibility of the ﬁrst click?
How well could you feel the ﬁrst click?
How would you rate the audibility of the second click?
How well could you feel the second click?
After removing the autoinjector, how clear was it to check that the
injection was fully given?
Part 3: Satisfaction (after phase
2)—overall satisfaction and
willing to accept the device
Overall, how satisﬁed were you with the autoinjector? Adjusted 5-point
Likert scale*How willing are you to use the autoinjector for your own
medication?
How is your overall impression of the autoinjector?
How would you rate the overall use of the autoinjector?
How would you rate the safety feature of the autoinjector?
Would you recommend this device to (other) RA-patients? Yes/neutral/no
* For example: 1/very useful; 2/useful; 3/no opinion; 4/useless; 5/very useless. Positive answers: ‘‘Yes’’ and the two ﬁrst
points of the adjusted 5-point Likert scale. Neutral answers: ‘‘Neutral’’ or ‘‘No opinion’’ (not taken into account in the total
number of answers). Negative answers: ‘‘No’’ and the two last points of the adjusted 5-point Likert scale. Positive response
rate: number of positive answers out of the sum of positive and negative answers
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of the second phase, the instructor interviewed
the subject and completed part 2 of the usability
questionnaire and part 3 (satisfaction) (Table 4).
The protocol, the informed consent form
and all other documents related to the study
were submitted for review to Independent Eth-
ics Committee and to ANSM (Agence Nationale
de Se´curite´ du Me´dicament et des produits de
sante´). These two regulatory authorities con-
firmed that this study didn’t meet the biomed-
ical research criteria as defined in Article
R.L1121-1 of the French Public Health Code.
Nevertheless, the Ethics Committee stated that
there was no ethical obstacle to do this study
(notification number: MD-092014).
Study Objectives
The primary objective of this study was to
evaluate the usability of the new MTX autoin-
jector based on the rate of correct handling
during the second phase ‘‘worst-case’’ injection
according to the ‘‘score card’’ and on the rate of
positive responses of the usability
questionnaire.
The secondary objectives were to assess the
understanding of IFU (usability questionnaire
part 1), the usability (usability questionnaire
part 2), the subject satisfaction (usability ques-
tionnaire part 3), and the correct device han-
dling during the first phase and the optimal
environment simulation during the second
phase.
Determination of the Sample Size
and Statistics
According to the recommendations by the FDA,
usability studies should include 15 subjects
from each major user group [10]. Therefore,
initially, three groups of 15 subjects were
scheduled to be enrolled in the study. As the
investigators had recruitment difficulties in
completing the first user group (RA patients
with Cochin score C20), they decided to stop
the recruitment process when 12 subjects were
enrolled in this group.
Statistical analyses were performed using
SAS version 9.1. Considering the sample sizes,
only descriptive analyses were performed.
The handling steps according to the ‘‘score
card’’ were considered correct if the observer
filled ‘‘Yes, immediately’’ or ‘‘Yes, but after some
hesitations or problems’’, and incorrect if ‘‘Not
at all’’ was filled (Table 2). The rate of correct
handling steps for each subject was the number
Table 4 Study ﬂowchart
Evaluation of injection
performances by the
















explanations provided by the










light, TV or radio on,
phone ringing)
During the simulation /
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of correct steps out of total number of answers.
A rate of 75% was considered as a ‘‘correct
handling of the device’’.
For the usability questionnaires were con-
sidered as positive answers ‘‘Yes’’, when the
choice was ‘‘Yes/No opinion/No’’ and the two
first points of the adjusted 5-point Likert scale
when applicable (Table 3). The neutral answers
were ‘‘No opinion’’ and the 3rd point of the
Likert scale; the neutral answers have not been
taken into account in the total number of
answers. Answers ‘‘No’’ and the two last points
of the Likert scale were considered as negative.
The positive response rate was calculated for
each subject as follows: number of positive
answers out of the sum of positive and negative
answers. A rate of 75% was considered as ‘‘pos-
itive usability’’. Safety analysis was carried out
on the full analysis set.
RESULTS
Demographic Data
Forty-two subjects were enrolled in the study
between November 2014 and March 2015 by
three rheumatologists. A total of 126 simulated
injections (three simulations per subject) were
performed and scored by the independent
observer. The demographic data in the full
analysis set (FAS) and in the different user
groups are detailed in the Table 5. The mean age
in the three user groups displayed no statisti-
cally significant differences. Disease duration
was different across the groups: in the first user
group (Cochin score C20) the disease duration
was around 20 years, whereas in the second user
group (Cochin score\20), it was only 9 years.
Positive Response Rate According
to the Usability Questionnaire
After the first injection and without any addi-
tional instruction, the great majority of subjects
(90.5%) displayed a positive response rate C75%
for the first two parts of the usability question-
naire (92% of RA patients with high hand dis-
ability, 80% of RA patients with mild hand
disability, and 100% and caregivers) (Fig. 3).
After the second phase, all the subjects of all the














Female, n (%) 9 (75%) 12 (80%) 11 (73%) 32 (76%)
Age (years), mean ± SD 61 ± 12 60 ± 11 54 ± 18 58 ± 14
Age of RA diagnosis (years), mean ± SD 40 ± 16 51 ± 12 NA NA
Cochin score, mean ± SD 34 ± 12 5 ± 6 NA NA
Fig. 3 Percentage of positive responses for the usability
questionnaire for the full analysis set
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three user groups displayed a positive response
rate C75% concerning the second and the third
part of the usability questionnaire, thus meet-
ing one of the primary objectives of the study.
Overall, the usability questionnaire, scored
[80% of positive answers for each question,
except for the question ‘‘Did you check the
tamper-evident seal of the autoinjector?’’ in the
Part 1, which scored 64.3% (Fig. 4). Although
sample sizes did not allow performing robust
statistical investigation, no major differences
were descriptively observed among the three
user groups.
In the Part 1, 64.3–100% of users indicated
that they checked properly the device’s quality,
and this before any additional explanation
potentially made by the instructor (questions
1–6). The IFU seemed clear and useful for
95–100% of subjects (questions 7–9). In Part 2,
concerning the subject device acceptance and
ease of use, completed twice (before and after
potential additional explanations), five patients
Fig. 4 Percentage of positive responses for the usability questionnaire for the full analysis set
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in the first group, one in the second group, and
one nurse indicated that they met some diffi-
culties with removing the cap from the
autoinjector. For all the other questions of this
part, the rate of positive answers was[80% after
the first phase and improved up to 100% after
the second phase. In Part 3, concerning satis-
faction, all the questions met 100% of positive
responses, with the exception of the last ques-
tion, which scored 97.5%.
Correct Performance Rate According
to the ‘‘Score Card’’
The great majority of subjects displayed a cor-
rect performance rate C75% during the first
phase (100% of the RA patients with high hand
disability, 93% of the RA patients with mild or
no hand disability and 93% of the caregivers).
During the second phase, 100% of subjects in
each of the three user groups displayed a correct
performance rate C75% in both optimal and
‘‘worst-case’’ environment, thus attaining the
co-primary objective of the study (Fig. 5).
Overall, the handling steps were conducted
successfully; more than 78% success for each
step, irrespective of the user group, previous
explanations, or environment conditions
(Fig. 6). Some difficulties could have appeared
during the first phase, especially concerning the
viewing window checking and the removal of
the device after the injection. All of these issues
seemed to disappear during the second phase,
after the instructor’s explanations. The injec-
tion itself steps were performed correctly for
100% of patients during all the phases. Notably,
the environmental conditions during the sec-
ond phase did not seem to influence the injec-
tion performances of the patients. The rate of
success in the second phase is over 97% for all
the handling steps.
Safety
No adverse events or deaths were reported dur-
ing the study.
DISCUSSION
The purpose of this multicenter study was to
assess the usability and the IFU understanding
of a newly developed MTX SC autoinjector in
subjects with variable manual dexterity and in
different environmental conditions. The differ-
ent user groups enrolled were comparable in
terms of age and sex ratio. The study met the
design requirements for the number of subjects
per user group [10].
The results demonstrate the high accep-
tance, usability, and intuitive handling of this
new device regardless of the hand disability or
environmental conditions. From 9 to 100% of
RA patients and caregivers found the IFU clear
and useful and were plenty satisfied with the
usability and handling of this new MTX
autoinjector. In the first phase, which consisted
of injection straight after IFU reading without
any further explanation, the great majority of
subjects displayed a correct performance rate
C75% according to the ‘‘score card’’ (93–100%
of users) and a positive response rate C75% for
the usability questionnaire (80–100% of users),
revealing a very intuitive device handling.
These scores grew up to 100% for all the subjects
during the second phase, performed after
potential instructor’s additional explanations,
Fig. 5 Percentage of subjects achieving over 75% of
correct handling steps according to the score card
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highlighting the importance of experience and
of therapeutic education. The points that nee-
ded to be particularly addressed during this
training seemed to be device quality and readi-
ness for injection checking and the importance
of hearing the ‘‘second click’’, which notifies the
end of the injection. This trial did not raise any
safety concerns, showing reliability and
robustness of the device tested on 126 simu-
lated injections.
Since few years autoinjector pens have been
introduced in the field of rheumatology for
biologic and conventional disease-modifying
anti-rheumatic drugs. Several studies showed
that patients with RA and other chronic disor-
ders, such as diabetes, have been found to prefer
autoinjectors when compared to more ‘‘classic’’
devices (vials or syringes), in particular because
they seem to be more convenient and easy to
use and less painful than prefilled syringes
[4, 5, 11–13]. Some patients even preferred these
devices over oral treatment and seemed to have
improved quality of life [14–16]. All of these
data confirm the interest of introducing for RA
patients new MTX autoinjectors, such as the
one assessed in this trial.
Limitations of this study consisted mainly of
the limited number of users, the simulated water
injections, the descriptive, more than analytical
character of the study, and the lack of compara-
tor. Such a randomized open-label trial is cur-
rently ongoing comparing the MTX autoinjector
presented here to MTX prefilled syringes in a
cohort of 280 patients with active RA (Clini-
calTrials.gov Identifier: NCT02553018).
CONCLUSIONS
This study found a very high level of usability,
acceptance, and satisfaction of a new MTX
autoinjector, regardless of the level of manual
Fig. 6 Percentage of subjects executing correct handling steps for the full analysis set according to the score card
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dexterity or environmental conditions. The
high performance rate and compliance with the
usability questionnaire during the first phase,
consisting of an injection immediately after
reading the IFU without further explanations,
showed an intuitive device handling and clarity
of the IFU. These findings show the interest
expressed by RA patients, nurses and caregivers
for this new MTX autoinjector.
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